Clinical trial NCT01412125: Study of Biomarkers That Predict the Evolution of Huntington's Disease
Official title: Study of Biomarkers That Predict the Evolution of Huntington's Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Huntington Disease
Keywords: Biomarkers
Genetic polymorphism
Neuroimaging markers
Neuropsychology
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2011-08-09
Enrollment: 1800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from Huntington disease (carrying the gene) versus healthy controls

Brief summary: Huntington's disease (HD) is a rare, autosomal dominant, progressive neurodegenerative disorder typically becoming noticeable in middle age. It is clinically characterized by progressive involuntary movements (bradykinesia and hyperkinesia), neuropsychiatric disturbances (depression, irritability), and cognitive impairments progressing to dementia.

The striatum (caudate and putamen) is the primary area of neuronal degeneration in HD. Today, there is no validated curative treatment. HD affects approximately 6 000 patients in France and more than 30 000 individuals are considered at risk for this disease.

While the disease gene is discovered and we are capable to do a predictive genetic diagnosis for asymptomatic patients, there is no clinical or biological way to predict the age of onset or the progressive profile of patients.

One of the fundamental characteristics of this disease is its extreme variability from one patient to other both in terms of their evolution and their onset of action. Thus, this inter-individual variability severely limits the genetic counselling and complicating the neurological assessment.

Increasingly, it has been assumed that modifier genes may be the source of this inter-individual variability and that their identification could help the understanding and prediction of disease progression.

Given that the mutant protein is ubiquitous, the molecular dysfunction of neurons could be found in peripheral cells from the bloodstream and will be more accessible to investigation.

Detailed description: In this context, we propose to focus our research not only on biological and genetic markers but also on neuroimaging and neuropsychological markers using paradigms of time reactions or measurement of evoked potentials. We hope to identify sensitive markers of the degenerative process of Huntington's disease even when patients carrying the gene may or may not have reported the disease.

The project is centered on 2 axes:

1. identification of the genetic polymorphism which may explain the phenotypic variability seeing in Huntington's disease
2. identification of biological, genetic and imaging biomarkers that could be used as predictors of clinical progression of Huntington's disease This research is based on the existence of a well followed and well characterized cohort of patients through the Francophone Huntington Network ("RESEAU HUNTINGTON de LANGUE FRANCAISE", RHLF). Therefore, this will help to combine the clinical and biological expertise of RHLF.

Eligibility criteria: Inclusion Criteria (patient):

* Voluntary patients symptomatic or asymptomatic
* Patient with a number of CAG ≥36)
* Patient who know his genetic status
* Age greater than 18 years or equal to 18 years
* Patient who provided written informed consent

Exclusion Criteria (patient):

- Deterioration of the protocol preventing the understanding of the protocol

Inclusion Criteria (control):

* Voluntary controls with no family history of huntington's disease
* Control with a number of CAG \<36
* Age greater than 18 years or equal to 18 years
* Control who provided written informed consent

Exclusion Criteria (control):

- Deterioration of the protocol preventing the understanding of the protocol

Primary outcomes:
measure: Unified Huntington Disease Rating Scale (UHDRS)
timeFrame: up to 9 years
Secondary outcomes:
measure: Mattis Dementia Rating Scale
timeFrame: up to 9 years
measure: Trail Making test A et B
timeFrame: up to 9 years
measure: Hopkins Verbal Learning Test
timeFrame: up to 9 years
measure: Categorical Fluency
timeFrame: up to 9 years
measure: Language tests
timeFrame: up to 9 years
measure: Social cognition tests
timeFrame: up to 9 years
measure: Comportment scale
timeFrame: up to 9 years
measure: Neuroimaging
timeFrame: up to 9 years
measure: Neuropsychological evaluation
timeFrame: up to 9 years
measure: Electrophysiological tests
timeFrame: up to 9 years
Other outcomes:
Locations:
city: Creteil
country: France
facility: Hôpital Henri Mondor
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Bachoud-Lévi Anne-Catherine, PH
role: PRINCIPAL_INVESTIGATOR
References: